American society of clinical oncology statement on minimum standards and exemplary attributes of clinical trial sites

被引:48
|
作者
Zon, Robin
Meropol, Neal J. [1 ]
Catalano, Robert B.
Schilsky, Richard L.
机构
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
关键词
D O I
10.1200/JCO.2007.15.6398
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To describe both minimum requirements for a site conducting quality clinical trials and attributes of an exemplary site. Methods Minimum requirements and exemplary attributes were selected based on literature review, prevailing regulatory requirements, and consensus among a group of community and academic clinical researchers. Results To provide guidance to oncologists who wish to conduct patient-oriented research, recommendations are made to assist in the development and implementation of high-quality research programs with the priority of protecting the welfare and rights of trial participants. A quality research site complies with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, the accepted international ethical and scientific quality standards for designing, conducting, recording, and reporting trials involving human participants. Recognizing that many research sites conduct clinical trials in compliance with accepted GCP standards, supplemental attributes of an exemplary research site that exceed the GCP criteria are also described. These attributes include diversification of clinical trial mix, high accrual activity, participation in the trial development process, maintenance of high educational standards, quality assurance, multidisciplinary involvement in the clinical trial process, and promotion of clinical trial awareness programs. Conclusion Meeting the minimum criteria ensures conduct of quality clinical trials; however, some sites may wish to incorporate value-added attributes to exceed GCP compliance. These attributes are proposed as performance goals rather than requirements, recognizing that all sites conducting research will not necessarily meet each attribute but may still conduct high-quality clinical trials.
引用
收藏
页码:2562 / 2567
页数:6
相关论文
共 50 条
  • [1] Implementing Clinical Trials: A Review of the Attributes of Exemplary Clinical Trial Sites
    Baer, Allison R.
    Cohen, Gary
    Smith, Dee Anna
    Zon, Robin
    JOURNAL OF ONCOLOGY PRACTICE, 2010, 6 (06) : 328 - 330
  • [2] American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology
    Zon, Robin T.
    Frame, James N.
    Neuss, Michael N.
    Page, Ray D.
    Wollins, Dana S.
    Stranne, Steven
    Bosserman, Linda D.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (03) : 261 - +
  • [3] American Society of Clinical Oncology Statement: Biosimilars in Oncology
    Lyman, Gary H.
    Balaban, Edward
    Diaz, Michael
    Ferris, Andrea
    Tsao, Anne
    Voest, Emile
    Zon, Robin
    Francisco, Michael
    Green, Sybil
    Sherwood, Shimere
    Harvey, R. Donald
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) : 1260 - +
  • [4] Part 2: Implementing Clinical Trials: A Review of the Attributes of Exemplary Clinical Trial Sites
    Zon, Robin
    Cohen, Gary
    Smith, Dee Anna
    Baer, Allison R.
    JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (01) : 61 - 64
  • [5] Alcohol and Cancer: A Statement of the American Society of Clinical Oncology
    LoConte, Noelle K.
    Brewster, Abenaa M.
    Kaur, Judith S.
    Merrill, Janette K.
    Alberg, Anthony J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (01) : 83 - +
  • [6] Comment on the American Society of Clinical Oncology Value Statement
    Weber, Jeffrey S.
    Drakeman, Donald L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2937 - +
  • [7] American Society of Clinical Oncology policy statement: Oversight of clinical research
    Schnipper, LE
    Atkins, M
    Beveridge, RA
    Brenner, D
    Bunn, P
    Coleman, E
    Comis, RL
    Einhorn, L
    Emanuel, E
    Fields, S
    Forastiere, A
    Gordon, BG
    Halberg, F
    Haluska, F
    Hortobagyi, G
    Kolker, A
    Miller, LL
    Norton, L
    Sallan, S
    Scherr, S
    Niederhuber, JE
    Baggstrom, MQ
    Balducci, L
    Bosserman, LD
    Bosworth, LL
    Brose, M
    Come, SE
    Cripe, LD
    Fisch, M
    Gesme, D
    Goldstein, N
    Gordon, BG
    Gostout, B
    Gralow, J
    Grunberg, SM
    Haluska, FG
    Hortobagyi, GN
    Klimberg, VS
    Kuzel, T
    Lessin, LS
    Pazdur, R
    Pfister, DG
    Raghavan, D
    Runowicz, CD
    Schnipper, LE
    Schuchter, LM
    Schwartz, BS
    Sigal, EV
    Stovall, E
    Ward, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2377 - 2386
  • [8] American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Safety Standards
    Gullatte, Mary
    JOURNAL OF ONCOLOGY PRACTICE, 2013, 9 (02) : 3S - 4S
  • [9] Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement
    Tsimberidou, Apostolia M.
    Levit, Laura A.
    Schilsky, Richard L.
    Averbuch, Steven D.
    Chen, Daniel
    Kirkwood, John M.
    McShane, Lisa M.
    Sharon, Elad
    Mileham, Kathryn F.
    Postow, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (01) : 72 - +
  • [10] Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement
    Tsimberidou, Apostolia M.
    Levit, Laura A.
    Schilsky, Richard L.
    Averbuch, Steven D.
    Chen, Daniel
    Kirkwood, John M.
    McShane, Lisa M.
    Sharon, Elad
    Mileham, Kathryn F.
    Postow, Michael A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6